Breast Implant Lawsuit 2026: Allergan BIA-ALCL Settlement & Bellwether Update
Breast implant lawsuit claims can involve recalled Allergan BIOCELL textured implants, breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), explant or revision surgery, rupture, capsular contracture and other serious complications. The largest active federal proceeding is Allergan BIOCELL MDL 2921 in the District of New Jersey, where major settlement and bellwether developments occurred in 2026.
Choose the Breast Implant Lawsuit Information You Need
Start with potential eligibility or MDL 2921, then review the Allergan recall, BIA-ALCL evidence, systemic symptoms, settlement factors or the calculator.
What Is a Breast Implant Lawsuit?
A breast implant lawsuit is a product-liability or related civil claim alleging that an implant or tissue expander was defectively designed, manufactured, labeled or marketed and caused a compensable injury. Current litigation does not treat every implant complication as one case category. The strongest active federal mass-tort proceeding centers on Allergan BIOCELL textured implants and tissue expanders, while rupture, contracture, systemic-symptom and malpractice claims may follow different legal paths.
BIOCELL Textured Implants
MDL 2921 coordinates federal claims involving Allergan BIOCELL textured breast implants and tissue expanders, including BIA-ALCL and other alleged injuries.
BIA-ALCL
BIA-ALCL is a T-cell lymphoma found most often in the fluid or capsule around a breast implant. It is not breast cancer.
Revision & Complication Cases
Rupture, capsular contracture, infection, malposition, explant or systemic-symptom claims may require different medical and legal proof.
Who May Qualify for a Breast Implant Lawsuit?
There is no single nationwide qualification rule. A case review usually starts with the implant manufacturer and surface type, the injury or diagnosis, pathology or surgical records, whether explant or revision was required, and the applicable filing deadline.
Confirmed BIA-ALCL
- Pathology, cytology or oncology records support the diagnosis.
- Implant history identifies Allergan BIOCELL or another relevant textured implant.
- Explant, capsulectomy, cancer treatment or monitoring records are available.
Recalled Textured Implant With Serious Harm
- Records identify a recalled BIOCELL implant or tissue expander.
- Documented complication required significant treatment or surgery.
- The injury and product history fit a legally actionable theory under applicable law.
Major Revision or Explant Injury
Rupture, severe capsular contracture, persistent seroma, infection, migration, recurrent surgery or significant reconstruction complications may warrant individualized review.
Systemic Symptoms / BII
Some patients report fatigue, joint pain, cognitive symptoms and other systemic complaints. FDA says Breast Implant Illness is not a formal diagnosis and the cause of these symptoms remains unclear, so these claims can be more causation-sensitive.
Allergan BIOCELL MDL 2921 Status in August 2026
In re: Allergan BIOCELL Textured Breast Implant Products Liability Litigation, MDL No. 2921, remains centralized in the District of New Jersey before Judge Brian R. Martinotti and Magistrate Judge Leda Dunn Wettre. JPML’s August 3, 2026 figures list 1,377 pending actions and 1,583 historical actions.
July 24, 2019 — BIOCELL Recall
FDA requested that Allergan recall specific textured breast implants and tissue expanders because of the BIA-ALCL risk; Allergan announced a worldwide recall.
December 18, 2019 — MDL 2921 Centralized
JPML transferred and centralized related federal Allergan BIOCELL cases in the District of New Jersey.
October 14, 2025 — Bellwether Trial Process
Case Management Order 37 established the process for selecting six bellwether trial cases and two initial trials.
June 2026 — ALCL Settlement Agreement
AbbVie disclosed that it reached an agreement to resolve substantially all U.S.-based ALCL lawsuits, which will be dismissed with prejudice. The filing did not publish individual settlement amounts.
July 13, 2026 — Henson and Rabin Selected
Judge Martinotti selected Henson as the first bellwether case for November 2, 2026 and Rabin as the second case to follow.
August 3, 2026 — 1,377 Actions Pending
JPML’s current statistics show a 119-case decline from July, but JPML counts alone do not identify why particular cases left the docket.
Which Allergan Breast Implants Were Recalled?
In July 2019, FDA requested a recall of specific Allergan BIOCELL textured breast implants and tissue expanders after concluding the BIA-ALCL risk was disproportionately associated with Allergan’s macrotextured BIOCELL surface. Allergan then announced a worldwide recall. The recall did not include Allergan smooth-surface breast implants.
Natrelle BIOCELL Textured Implants
The recall included multiple Natrelle saline and silicone-filled textured product styles, including Natrelle 410 and certain Natrelle INSPIRA textured implants.
McGhan / BIOCELL Products
Various McGhan BIOCELL textured breast implant styles were included in the recall.
BIOCELL Tissue Expanders
Certain Natrelle 133 and related BIOCELL textured tissue expanders were also included.
BIA-ALCL and Textured Breast Implants
Breast Implant-Associated Anaplastic Large Cell Lymphoma is a T-cell lymphoma associated with breast implants, particularly textured-surface devices. FDA says BIA-ALCL is usually found in the fluid or fibrous capsule around an implant rather than in breast tissue itself.
FDA’s current MDR summary reports 1,380 U.S. and worldwide BIA-ALCL cases reported to the agency as of June 30, 2024. That figure is a medical-device reporting total—not an incidence rate. FDA cautions that MDR data can be incomplete, duplicated or otherwise limited and should be interpreted together with other evidence.
Persistent Swelling / Seroma
Late fluid accumulation around an implant can be one presentation that warrants medical evaluation.
Mass or Lump
A peri-implant mass, capsular change or lymph-node finding may require imaging and pathology.
Pathology Evidence
Diagnosis commonly involves fluid or tissue evaluation including CD30 and ALK-related testing interpreted by qualified specialists.
Treatment
FDA notes that treatment generally includes removal of the implant and surrounding capsule; some patients also require chemotherapy or radiation.
Breast Implant Illness: What FDA Says
“Breast Implant Illness” or BII is a term used by patients and some clinicians to describe systemic symptoms reported after breast implantation. FDA says BII is not currently recognized as a formal medical diagnosis and there are no specific tests or established diagnostic criteria that define it.
Reported Symptoms
Patients have reported fatigue, joint or muscle pain, “brain fog,” hair loss, anxiety, depression, rashes, weight changes and other systemic complaints.
Cause Remains Unclear
FDA has received systemic-symptom reports involving different implant fill types, shapes and surfaces, but the cause and degree of implant-relatedness remain uncertain.
Some Report Improvement
Some patients report improvement after explantation, but voluntary reports cannot determine how often improvement occurs or prove why symptoms changed.
Rupture, Capsular Contracture and Other Cancers Around Implants
FDA identifies multiple known breast implant complications, including rupture or deflation, capsular contracture, pain, infection, seroma, malposition and the need for additional surgery. FDA also has reported rare cases of squamous cell carcinoma and lymphomas other than BIA-ALCL arising in the capsule around breast implants.
Rupture / Deflation
Silicone rupture may be “silent” and detected through imaging; saline rupture typically produces visible deflation.
Capsular Contracture
Scar tissue around the implant can tighten, become painful or distort the breast and may require revision surgery.
SCC and Other Lymphomas
FDA has reported rare SCC and non-BIA-ALCL lymphoma cases in the capsule. These conditions are distinct from BIA-ALCL and have different evidence.
Evidence That Can Strengthen a Breast Implant Claim Review
Implant Card / Product Records
Manufacturer, model, texture, serial number, lot number and implant date can establish product identity.
Original Operative Report
The implantation record may contain device stickers, product information, surgical details and facility information.
Pathology / Biopsy
BIA-ALCL and other capsule-cancer claims depend heavily on pathology, cytology, CD30/ALK-related evidence and oncology documentation.
Imaging
Ultrasound, MRI, mammography, PET/CT or other imaging may document seroma, rupture, masses, lymph nodes or implant position.
Explant / Capsulectomy Records
Operative findings can document capsule condition, fluid, rupture, implant surface, pathology sampling and reconstruction.
Oncology / Treatment Records
Cancer staging, surgery, chemotherapy, radiation, surveillance and follow-up can establish severity and treatment burden.
Revision & Reconstruction Records
Repeated surgeries, scarring, malposition, rupture or reconstructive complications can affect damages.
Economic & Life Impact
Medical bills, lost wages, travel, caregiving, disability, scarring and long-term medical needs may support damages.
Breast Implant Lawsuit Settlement Status and Value Factors
The most important 2026 settlement development is AbbVie’s disclosure that it reached an agreement in June to resolve substantially all U.S.-based ALCL lawsuits involving Allergan BIOCELL textured implants. The filing says those lawsuits will be dismissed with prejudice but does not disclose a universal settlement amount, tier schedule or individual payout figures.
Confirmed BIA-ALCL
Diagnosis, stage, pathology, oncology treatment, surgery and long-term monitoring can materially affect damages.
Implant Identification
Clear proof of Allergan BIOCELL or another relevant product can materially affect liability and settlement eligibility.
Explant / Capsulectomy
Medical necessity, surgical burden, pathology findings, reconstruction and complications can affect damages.
Other Serious Complications
Rupture, severe contracture, infection, repeated surgery or permanent disfigurement can produce different claim values and defenses.
Economic Loss
Medical costs, lost income, future care, monitoring, caregiving and travel expenses may be relevant where legally recoverable.
State Law & Defenses
Statutes of limitation, warning law, causation, product identification and prior settlements can materially change outcomes.
How a Breast Implant Lawsuit May Be Evaluated
Identify the Implant
Obtain implant cards, operative records, manufacturer stickers and model information.
Confirm the Diagnosis
Collect pathology, imaging, oncology, revision or other injury-specific records.
Build the Timeline
Map implantation, symptom onset, diagnosis, recall awareness, explant and treatment dates.
Review Causation
Evaluate implant type, alternative causes, medical evidence and expert requirements.
Check Litigation & State Law
Determine whether MDL 2921, state-court litigation or an individual claim path applies.
Document Damages
Preserve treatment costs, lost income, future care, scarring, disability and other supported losses.
Breast Implant Lawsuit Statute of Limitations
There is no single nationwide deadline for every breast implant claim. State statutes of limitation and repose can depend on implant date, symptom onset, diagnosis, recall information, discovery of a possible product connection, explantation, cancer diagnosis, prior claims and other facts.
Breast Implant Lawsuit FAQ
How many Allergan breast implant lawsuits are pending?
JPML’s August 3, 2026 figures list 1,377 actions pending and 1,583 historical actions in Allergan BIOCELL MDL 2921.
Did Allergan settle the BIA-ALCL lawsuits?
AbbVie reported that in June 2026 it reached an agreement to resolve substantially all U.S.-based ALCL lawsuits, which will be dismissed with prejudice. The filing does not disclose a universal payout amount and does not say that every remaining MDL claim is resolved.
When is the first Allergan BIOCELL bellwether trial?
On July 13, 2026, Judge Brian R. Martinotti selected Henson as the first bellwether case for trial on November 2, 2026 and Rabin as the second case to follow.
Are all breast implants linked to BIA-ALCL?
FDA says BIA-ALCL occurs more frequently in patients with textured-surface implants than smooth implants. The 2019 Allergan recall involved specific BIOCELL textured implants and tissue expanders, not Allergan smooth implants.
Is Breast Implant Illness an official diagnosis?
No. FDA says BII is a term used for systemic symptoms reported by some patients, but it is not currently a formal diagnosis and has no established diagnostic test or criteria.
Should an asymptomatic patient remove a recalled BIOCELL implant?
FDA has not recommended routine removal of recalled BIOCELL textured implants in patients without symptoms solely because of the recall. Medical decisions should be made with a qualified clinician.
What records are most important for a breast implant claim?
Implant cards, operative reports, manufacturer/model information, pathology or biopsy records, oncology records, imaging, explant or revision records, bills and lost-income evidence can all be important.
How much is a breast implant lawsuit worth?
There is no reliable universal average. Diagnosis, implant type, pathology, treatment, explant surgery, long-term harm, damages, causation, state law and settlement participation can all materially change value.
Breast Implant Lawsuit Sources and Official References
- District of New Jersey — Allergan BIOCELL Textured Breast Implant Products Liability Litigation. Official MDL 2921 page.
- Judicial Panel on Multidistrict Litigation — Pending MDL Reports. August 3, 2026 figures list 1,377 pending and 1,583 historical actions in MDL 2921.
- District of New Jersey — July 13, 2026 bellwether opinion. Selects Henson for Nov. 2, 2026 and Rabin as the second bellwether.
- AbbVie 2026 Form 10-Q. Reports the June 2026 agreement resolving substantially all U.S.-based ALCL lawsuits and describes remaining breast-implant litigation.
- FDA — July 24, 2019 Allergan BIOCELL recall request. Identifies the recalled textured implant and tissue-expander families.
- FDA — BIA-ALCL Medical Device Reports. Reports 1,380 U.S. and worldwide MDR cases as of June 30, 2024 and explains reporting limitations.
- FDA — Questions and Answers About BIA-ALCL. Symptoms, implant identification, diagnosis and safety recommendations.
- FDA — Risks and Complications of Breast Implants. Rupture, capsular contracture, BIA-ALCL and other recognized concerns.
- FDA — SCC and Other Cancers in the Breast Implant Capsule. Separate safety communication for rare capsule cancers distinct from BIA-ALCL.
Request a Confidential Breast Implant Case Review
If you have a confirmed BIA-ALCL diagnosis, a recalled textured implant, major explant or revision surgery, or another serious breast implant complication, submit the implant, diagnosis, treatment and timing information you know now for review.
